| Product Name page | Expected Species Reactivity | Applications |
|---|---|---|
| Anti-A14 [BB5.2] | Vaccinia virus | WB; IP; IF |
| Anti-Vaccinia A33 glycoprotein [A2C7] | Vaccinia virus | IF; neutralization |
| Anti-Vaccinia L1 protein [M12b9 Fab] | Vaccinia virus | crystallization; BLI binding assay |
Anti-Vaccinia A33 glycoprotein抗體 | Fc Silent™ Antibodies系列有效降低非特異性Fc結合。
特點
Fc Silent™ Antibodies: Turning down the background noise
Fc Silent 抗體 | 只要訊號不要雜訊 (Engineered Fc Domain)
Absolute Antibody 提供一系列抗體商品，其中Fc Silent™ Antibodies系列；能有效降低非特異性Fc結合。Fc Silent™技術，為應用生物工程技術，將Fc receptors (FcγR, FcR)點突變，進而中止抗體與ADCC的功能；有效降低Fc所造成的背景訊號。
Fc Silent™抗體應用於免疫細胞時flow cytometry、immunohistochemistry (IHC)資料顯示，有效降低非特異性之Fc結合，所造成的背景值。(訂購抗體前，請確認選擇抗體是否有Fc Silent™修飾標誌)
Anti-Vaccinia A33 glycoprotein抗體 | 產品描述:
Recombinant monoclonal antibody to Vaccinia A33 glycoprotein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma A2C7.
| 抗體名稱 | Anti-Vaccinia A33 glycoprotein [A2C7] | |
| 抗體貨號 | 特異性This antibody is specific for the VACV antigen A33, a viral glycoprotein associated with the outer membrane of extracellular enveloped viruses. A33 is known to elicit protective antibody responses. | |
| This antibody was prepared by intranasally infecting BALB/c mice with an attenuated vaccinia virus (VACV) mutant, followed by a boost with an intravenous injection of UV-inactivated WT VACV. | ||
| 免疫原 | This antibody is specific for the VACV antigen A33, a viral glycoprotein associated with the outer membrane of extracellular enveloped viruses. A33 is known to elicit protective antibody responses. | |
| 應用注意 | The specificity of this antibody for VACV has been confirmed by IF assays (Meng, 2011). This antibody exhibited strong complement-mediated neutralization of the extracellular enveloped form of vaccinia virus in the presence of complement, and was able to protect mice against weight loss and death following an in vivo VACV challenge (Matho, 2015). | |
更多相關抗體Primary Antibodies